Targeting tumor-associated macrophages for cancer immunotherapy

Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188434. doi: 10.1016/j.bbcan.2020.188434. Epub 2020 Sep 18.

Abstract

Macrophages are important effector cells of the innate immune system and are also major components of the tumor microenvironment (TME). Macrophages that are abundant in the TME are called tumor-associated macrophages (TAMs). As TAMs promote strong tumor angiogenesis and support tumor cell survival, they are closely related to tumor growth. Several studies have demonstrated that reducing the density or effects of TAMs can inhibit the growth of tumors, making them targets for cancer immunotherapy, which has become a research hot spot. Several clinical and preclinical trials have studied drugs that inhibit the effects of and reduce the population of phagocytes that target TAMs achieve cancer immunotherapy. In this paper, we summarize the various methods of targeting TAMs for tumor immunotherapy, focusing on TAM mechanisms, sources, and polarization.

Keywords: Immunotherapy; Tumor; Tumor-associated macrophages (TAMs).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Combined Modality Therapy
  • Drug Therapy
  • Humans
  • Immunotherapy
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Radiotherapy
  • Signal Transduction / drug effects
  • Tumor Microenvironment / drug effects
  • Tumor-Associated Macrophages / drug effects*
  • Tumor-Associated Macrophages / metabolism

Substances

  • Antineoplastic Agents, Immunological